Front Desk: 469-391-0070
Multiple Myeloma: Symptoms, Diagnosis, and Treatment Options
Introduction
Plasma cell myeloma, commonly known as multiple myeloma, is a type of cancer that affects plasma cells, a form of white blood cell found in the bone marrow. These cells are responsible for producing antibodies that help the body fight infections. In multiple myeloma, abnormal plasma cells multiply uncontrollably, crowding out healthy cells and leading to various health complications. This condition can affect the bones, immune system, kidneys, and red blood cell count.
This article provides a comprehensive overview of multiple myeloma, covering its risk factors, symptoms, diagnostic tests, treatment options, and ways patients can manage symptoms at home. Understanding these aspects empowers patients to work closely with healthcare providers to make informed decisions about their care and treatment.
Definition
Plasma cell myeloma (multiple myeloma) is a cancer of the plasma cells. It involves several key aspects, including risk factors, symptoms, diagnostic tests, medications, procedures, and lifestyle changes that can help manage symptoms.
Description of Plasma Cell Myeloma (Multiple Myeloma)
Plasma cell myeloma, or multiple myeloma, originates in the plasma cells of the bone marrow. Plasma cells are essential to the immune system, producing antibodies that help fight infections. In multiple myeloma, these plasma cells become cancerous and multiply uncontrollably. As the number of abnormal plasma cells increases, they interfere with the production of normal blood cells, leading to anemia, infections, and other complications.
Multiple myeloma typically progresses in stages. In the early stages, patients may not experience symptoms, a phase known as “smoldering myeloma.” As the disease advances, symptoms such as bone pain, fatigue, and frequent infections may develop. In severe cases, multiple myeloma can lead to kidney damage, bone fractures, and elevated calcium levels in the blood (hypercalcemia).
According to the American Cancer Society, multiple myeloma accounts for about 1.8% of all cancers in the United States. It is more common in older adults, with the average age of diagnosis around 69 years. Men are slightly more likely to develop the disease than women, and it is more prevalent in African Americans than in other racial groups.
Risk Factors for Developing Plasma Cell Myeloma (Multiple Myeloma)
Lifestyle Risk Factors
While lifestyle factors are not the primary cause of multiple myeloma, certain habits may increase the risk. Smoking, for instance, is linked to a higher risk of various cancers, including multiple myeloma. Additionally, exposure to certain chemicals, such as those found in pesticides, herbicides, and industrial environments, may elevate the risk. Maintaining a healthy lifestyle, including regular exercise and a balanced diet, can help reduce the overall risk of cancer, though it may not specifically prevent multiple myeloma.
Medical Risk Factors
Several medical conditions can increase the likelihood of developing multiple myeloma. Individuals with a history of monoclonal gammopathy of undetermined significance (MGUS), a condition where abnormal plasma cells produce a protein called monoclonal protein, are at higher risk. MGUS is considered a precursor to multiple myeloma, though not everyone with MGUS will develop the disease. Additionally, individuals with weakened immune systems, either due to chronic infections or autoimmune diseases, may have an increased risk of developing plasma cell myeloma.
Exposure to radiation, whether through medical treatments or environmental factors, has also been associated with a higher risk of multiple myeloma. Patients who have undergone radiation therapy for other cancers may have a slightly elevated risk of developing this condition later in life.
Genetic and Age-Related Risk Factors
Genetics play a significant role in the development of multiple myeloma. Individuals with a family history of the disease are more likely to develop it. While the exact genetic mutations leading to multiple myeloma are still being studied, researchers have identified certain chromosomal abnormalities common in patients with the disease.
Age is another important risk factor. Multiple myeloma is rare in people under 40, with most cases occurring in individuals over 65. As people age, their immune systems weaken, increasing the likelihood of developing cancer. Additionally, men are slightly more likely to develop multiple myeloma than women, though the reasons for this gender difference are not fully understood.
Clinical Manifestations of Multiple Myeloma
Fatigue
Fatigue is one of the most common symptoms of plasma cell myeloma, affecting approximately 70% of patients. This overwhelming tiredness can result from anemia, a reduction in red blood cells. In multiple myeloma, cancerous plasma cells crowd out healthy bone marrow cells, reducing red blood cell production. This leads to less oxygen being delivered to tissues, causing fatigue. Additionally, the disease itself can cause a general feeling of malaise, and treatments like chemotherapy may exacerbate this symptom.
Bone Pain
Bone pain occurs in about 60% of patients with multiple myeloma. The pain is often localized to the back, ribs, or hips and is caused by the overproduction of abnormal plasma cells in the bone marrow. These cells release substances that stimulate osteoclasts, which break down bone tissue. As a result, bones become weaker and more prone to fractures, leading to significant discomfort. Bone pain is often more pronounced in advanced stages of the disease and can be a key indicator of bone damage or lesions.
Anemia
Anemia affects around 60% of multiple myeloma patients. It occurs when the bone marrow cannot produce enough red blood cells due to the infiltration of cancerous plasma cells. Anemia can lead to symptoms like fatigue, shortness of breath, and dizziness. In some cases, anemia may be the first sign of multiple myeloma, especially in older adults. Treating the underlying myeloma can help improve anemia, but blood transfusions or medications to stimulate red blood cell production may also be necessary.
Hypercalcemia
Hypercalcemia, or elevated calcium levels in the blood, affects about 30% of patients with multiple myeloma. This occurs because the breakdown of bone releases calcium into the bloodstream. High calcium levels can cause symptoms like nausea, vomiting, constipation, confusion, and, in severe cases, kidney failure. Hypercalcemia is more common in advanced stages of the disease when bone destruction is more pronounced. Prompt treatment is necessary to prevent complications.
Renal Dysfunction
Renal dysfunction, or kidney problems, is seen in approximately 20-40% of multiple myeloma patients. The abnormal proteins produced by cancerous plasma cells can accumulate in the kidneys, leading to damage. Additionally, high calcium levels from bone breakdown can further strain the kidneys. Symptoms of kidney dysfunction may include swelling in the legs, fatigue, and changes in urination. In severe cases, dialysis may be required to manage kidney failure.
Recurrent Infections
Recurrent infections are common in multiple myeloma, affecting about 30% of patients. The disease weakens the immune system by reducing the number of healthy white blood cells, which are crucial for fighting infections. Patients may experience frequent respiratory infections, urinary tract infections, or other bacterial and viral illnesses. Infections can be more severe and harder to treat in multiple myeloma patients, making preventive measures like vaccinations and antibiotics important.
Weight Loss
Unintentional weight loss occurs in about 20% of multiple myeloma patients. This can result from a combination of factors, including loss of appetite, increased energy expenditure from the cancer, and the body’s inability to absorb nutrients properly. Weight loss is often a sign of advanced disease and may be accompanied by other symptoms like fatigue and weakness. Nutritional support and treatment of the underlying myeloma can help manage this symptom.
Night Sweats
Night sweats affect around 15% of multiple myeloma patients. These episodes of excessive sweating during sleep can be caused by the body’s response to the cancer or as a side effect of treatments like chemotherapy. Night sweats can disrupt sleep and contribute to fatigue. Managing the underlying disease and adjusting treatment regimens can help reduce the frequency and severity of night sweats.
Weakness
Weakness is a common symptom in multiple myeloma, affecting about 50% of patients. This can be caused by anemia, bone pain, or general malaise from the disease. Weakness may be localized to specific areas of the body, especially if bone damage or fractures are present. In some cases, weakness can be severe enough to interfere with daily activities. Treatment of the underlying myeloma and supportive care can help improve strength and energy levels.
Easy Bruising
Easy bruising occurs in about 20% of multiple myeloma patients. This is due to a reduction in platelets, the blood cells responsible for clotting. As cancerous plasma cells take over the bone marrow, platelet production decreases, making it easier for patients to bruise or bleed. In some cases, patients may also experience frequent nosebleeds or prolonged bleeding from minor cuts. Treatment of the underlying myeloma can help improve platelet counts and reduce the risk of bruising.
Diagnostic Evaluation of Multiple Myeloma
The diagnosis of plasma cell myeloma (multiple myeloma) is made through a combination of clinical evaluation, laboratory tests, and imaging studies. Doctors typically begin by reviewing the patient’s symptoms and medical history, followed by a physical examination. Blood tests, urine tests, and imaging studies are then used to confirm the diagnosis. A bone marrow biopsy is often required to assess the extent of plasma cell infiltration in the bone marrow. In some cases, additional tests such as cytogenetic analysis may be performed to determine the genetic abnormalities associated with the disease. Early diagnosis is crucial for initiating treatment and improving outcomes.
Blood Tests
Blood tests are a critical component of diagnosing multiple myeloma. These tests measure various substances in the blood, including calcium levels, kidney function markers, and proteins produced by cancerous plasma cells. A complete blood count (CBC) is often performed to check for anemia, which is common in multiple myeloma patients. Additionally, blood tests can measure the levels of monoclonal proteins (M proteins) and free light chains, which are produced by abnormal plasma cells.
Results that Indicate Plasma Cell Myeloma
Elevated levels of M proteins or free light chains in the blood are strong indicators of multiple myeloma. High calcium levels (hypercalcemia) and abnormal kidney function tests may also suggest the presence of the disease. If blood tests show these abnormalities, further testing, such as a bone marrow biopsy, is usually recommended to confirm the diagnosis. If the blood tests are normal but symptoms persist, additional diagnostic evaluations may be necessary.
Bone Marrow Biopsy
A bone marrow biopsy is a procedure in which a small sample of bone marrow is removed and examined under a microscope. This test is essential for confirming the diagnosis of multiple myeloma, as it allows doctors to assess the number of plasma cells in the bone marrow. The biopsy is typically performed using a needle inserted into the hip bone, and the procedure is done under local anesthesia.
Results that Indicate Plasma Cell Myeloma
In multiple myeloma, the bone marrow biopsy will show an increased number of abnormal plasma cells. Typically, more than 10% of the bone marrow cells will be plasma cells in patients with multiple myeloma. If the biopsy shows a high percentage of plasma cells, this confirms the diagnosis. If the biopsy is negative but symptoms persist, additional tests may be needed to rule out other conditions or to detect early-stage disease.
Imaging Tests
Imaging tests such as X-rays, CT scans, MRIs, and PET scans are used to assess bone damage and the spread of multiple myeloma. These tests can detect bone lesions, fractures, and areas of bone thinning caused by the disease. Imaging studies are also helpful in determining the extent of the disease and guiding treatment decisions.
Results that Indicate Plasma Cell Myeloma
Imaging tests may reveal lytic lesions (areas of bone destruction), fractures, or other signs of bone damage, which are common in multiple myeloma. If imaging studies show these abnormalities, it strongly suggests the presence of the disease. If imaging tests are normal but symptoms such as bone pain persist, further evaluation may be needed to detect early bone involvement.
Serum Protein Electrophoresis
Serum protein electrophoresis (SPEP) is a blood test that measures the levels of different proteins in the blood. This test is used to detect monoclonal proteins (M proteins), which are produced by abnormal plasma cells in multiple myeloma. SPEP is a key diagnostic tool for identifying the presence of these abnormal proteins.
Results that Indicate Plasma Cell Myeloma
The presence of a monoclonal protein spike (M spike) on the SPEP test is a hallmark of multiple myeloma. This spike indicates the overproduction of a single type of antibody by cancerous plasma cells. If an M spike is detected, further testing is usually performed to confirm the diagnosis. If the SPEP test is negative but symptoms persist, additional tests such as a bone marrow biopsy may be needed.
Urine Protein Electrophoresis
Urine protein electrophoresis (UPEP) is a test that measures the levels of proteins in the urine. In multiple myeloma, abnormal proteins called Bence Jones proteins may be present in the urine. This test is often used in conjunction with blood tests to diagnose the disease.
Results that Indicate Plasma Cell Myeloma
The presence of Bence Jones proteins in the urine is a strong indicator of multiple myeloma. If these proteins are detected, it suggests that the disease is affecting the kidneys. If the UPEP test is negative but symptoms persist, further testing may be needed to rule out other conditions or to detect early-stage disease.
What if All Tests are Negative but Symptoms Persist?
If all diagnostic tests come back negative but symptoms such as fatigue, bone pain, or recurrent infections persist, it is important to continue working with your healthcare provider. In some cases, multiple myeloma may be in its early stages and not yet detectable by standard tests. Your doctor may recommend repeating tests after a period of time or exploring other potential causes for your symptoms. It is crucial to advocate for your health and seek further evaluation if you feel that something is wrong.
Treatment Options for Multiple Myeloma
Medications for Plasma Cell Myeloma
Bortezomib
Definition: Bortezomib is a proteasome inhibitor that treats multiple myeloma by preventing cancer cells from breaking down proteins, ultimately leading to their death.
How and When It’s Used: Often a first-line treatment, Bortezomib can be used alone or in combination with other drugs like dexamethasone. It is administered either by injection or intravenously and is effective for both newly diagnosed and relapsed patients.
Expected Outcomes: Patients typically experience a reduction in cancerous plasma cells, improved blood counts, and relief from symptoms within weeks of starting treatment.
Lenalidomide
Definition: Lenalidomide is an immunomodulatory drug that enhances the immune system’s ability to fight cancer cells while also inhibiting their growth.
How and When It’s Used: Lenalidomide is commonly combined with dexamethasone for both newly diagnosed and relapsed cases of multiple myeloma. Taken orally, it is often part of long-term maintenance therapy to help keep the disease in remission.
Expected Outcomes: Lenalidomide helps slow disease progression and improve survival rates, with symptom improvements typically seen within a few months.
Dexamethasone
Definition: Dexamethasone is a corticosteroid that reduces inflammation and suppresses the immune system, helping to control the growth of myeloma cells.
How and When It’s Used: Dexamethasone is often combined with other treatments like bortezomib or lenalidomide. It can be taken orally or intravenously and is used in both initial and relapse treatments.
Expected Outcomes: Dexamethasone can quickly alleviate symptoms such as bone pain and fatigue, with noticeable improvements often seen within days to weeks.
Carfilzomib
Definition: Carfilzomib is a proteasome inhibitor that blocks proteasome activity, leading to the death of myeloma cells.
How and When It’s Used: Carfilzomib is typically used for patients who have relapsed or are resistant to other treatments. It is administered intravenously, often in combination with dexamethasone or lenalidomide.
Expected Outcomes: Carfilzomib can significantly reduce myeloma cell counts, with many patients experiencing remission or disease stabilization within a few months.
Pomalidomide
Definition: Pomalidomide is an immunomodulatory drug that helps the immune system attack cancer cells and inhibits their growth.
How and When It’s Used: Pomalidomide is generally used for patients who have relapsed after treatments like lenalidomide and bortezomib. It is taken orally and often combined with dexamethasone.
Expected Outcomes: Pomalidomide can slow disease progression and improve survival in relapsed multiple myeloma patients, with results typically seen within a few months.
Thalidomide
Definition: Thalidomide is an immunomodulatory drug that slows myeloma cell growth and enhances the immune system’s ability to fight the disease.
How and When It’s Used: Thalidomide is often combined with dexamethasone, particularly in newly diagnosed patients. It is taken orally and sometimes used as part of maintenance therapy.
Expected Outcomes: Thalidomide can reduce myeloma cells and improve symptoms, with improvements often seen within a few months.
Daratumumab
Definition: Daratumumab is a monoclonal antibody that targets a specific protein on myeloma cells, helping the immune system destroy them.
How and When It’s Used: Daratumumab is typically used for patients who have relapsed or are resistant to other treatments. It is administered intravenously or subcutaneously, often in combination with lenalidomide or bortezomib.
Expected Outcomes: Daratumumab can lead to significant reductions in myeloma cell counts, with many patients experiencing remission or disease stabilization within a few months.
Isatuximab
Definition: Isatuximab is a monoclonal antibody that targets a protein on myeloma cells, helping the immune system destroy them.
How and When It’s Used: Isatuximab is typically combined with drugs like pomalidomide for patients who have relapsed or are resistant to other treatments. It is administered intravenously.
Expected Outcomes: Isatuximab can reduce myeloma cells and slow disease progression, with improvements often seen within a few months.
Elotuzumab
Definition: Elotuzumab is a monoclonal antibody that targets a protein on myeloma cells, enhancing the immune system’s ability to destroy them.
How and When It’s Used: Elotuzumab is typically combined with lenalidomide or pomalidomide for patients who have relapsed or are resistant to other treatments. It is given intravenously.
Expected Outcomes: Elotuzumab can slow disease progression and improve survival, with results typically seen within a few months.
Melphalan
Definition: Melphalan is a chemotherapy drug that damages the DNA of myeloma cells, preventing them from growing and dividing.
How and When It’s Used: Melphalan is often used in high doses before a stem cell transplant or in lower doses for patients not eligible for transplant. It can be taken orally or intravenously.
Expected Outcomes: Melphalan can significantly reduce myeloma cell counts, with improvements often seen within weeks to months.
Improving Plasma Cell Myeloma (Multiple Myeloma) and Seeking Medical Help
While medical treatments are essential for managing multiple myeloma, several home remedies and lifestyle changes can enhance your quality of life and overall health:
- Hydration: Staying well-hydrated supports kidney function, which can be affected by multiple myeloma.
- Balanced Diet: A diet rich in fruits, vegetables, lean proteins, and whole grains helps maintain strength and energy levels.
- Regular Exercise: Gentle activities like walking or yoga can improve strength, reduce fatigue, and enhance mood.
- Stress Management: Techniques such as meditation, deep breathing, or counseling can help manage the emotional stress of living with a chronic illness.
- Adequate Sleep: Getting enough rest is crucial for healing and recovery.
- Avoiding Tobacco: Smoking worsens overall health and increases the risk of complications.
- Limiting Alcohol: Reducing alcohol intake protects the liver and kidneys, which may be affected by the disease and its treatments.
- Maintaining a Healthy Weight: A healthy weight reduces strain on the body and improves overall well-being.
- Staying Informed: Understanding your condition and treatment options empowers you to make informed decisions and feel more in control of your health.
Telemedicine offers a convenient way to stay in touch with your healthcare provider, allowing you to discuss symptoms, review test results, and adjust treatments without leaving home. If you experience new or worsening symptoms, such as increased bone pain, fatigue, or signs of infection, seek medical help promptly. Telemedicine provides quick access to care, ensuring early intervention.
Living with Plasma Cell Myeloma (Multiple Myeloma): Tips for Better Quality of Life
Living with multiple myeloma can be challenging, but there are steps you can take to improve your quality of life:
- Stay Active: Engage in light physical activities to maintain strength and mobility.
- Manage Pain: Work with your healthcare provider to find effective pain management strategies, such as medications or physical therapy.
- Emotional Support: Consider joining a support group or speaking with a counselor to cope with the emotional aspects of living with a chronic illness.
- Follow Your Treatment Plan: Adhering to prescribed medications and treatments helps control the disease and improve outcomes.
- Stay Connected: Keep in touch with family and friends to maintain a strong support network.
Conclusion
Plasma cell myeloma, or multiple myeloma, is a complex condition that requires ongoing medical care. Early diagnosis and treatment are crucial for managing symptoms, slowing disease progression, and improving quality of life. With advancements in medications and therapies, many patients achieve remission and live longer, healthier lives.
If you or a loved one has been diagnosed with multiple myeloma, staying proactive in your care is essential. Our telemedicine practice offers a convenient way to stay connected with your healthcare team, ensuring you receive the support and treatment you need. Reach out to us today to schedule a consultation and take the next step in managing your health.
